In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that ...

A multivariate analysis confirmed the independent prognostic significance of both landmark and longitudinal MRD.

As previously reported, Craig-Hallum initiated coverage of Personalis (PSNL) with a Buy rating and $8 price target. The firm notes Personalis ...

In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that measures the presence of ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that the U.S. Patent and ...

Circulating tumor DNA may be a prognostic biomarker for relapse and early recurrence detection in resected early-stage ...

Personalis, Inc. (Nasdaq: PSNL), in collaboration with Professor Nick Turner, Dr. Isaac Garcia-Murillas and their colleagues at The Institute of Cance ...

This builds on Natera’s extensive intellectual property estate, including a strong portfolio of molecular residual disease ... of preparation useful for tumor-informed ctDNA monitoring using ...